Novo Nordisk ADR (NYSE: NVO) on Tuesday, plunged -1.86% from the previous trading day, before settling in for the closing price of $109.09. Within the past 52 weeks, NVO’s price has moved between $94.73 and $148.15.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 14.25% over the past five years. The company achieved an average annual earnings per share of 21.54%. With a float of $3.34 billion, this company’s outstanding shares have now reached $3.38 billion.
Let’s look at the performance matrix of the company that is accounted for 63370 employees. In terms of profitability, gross margin is 84.53%, operating margin of 43.26%, and the pretax margin is 43.77%.
Novo Nordisk ADR (NVO) Insider and Institutional Ownership
Observing investor behavior towards Drug Manufacturers – General industry stocks is more important than anything else. The insider ownership of Novo Nordisk ADR is 0.02%, while institutional ownership is 10.06%.
Novo Nordisk ADR (NVO) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported 0.7 earnings per share (EPS) for the period topping the consensus outlook (set at 0.64) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.94 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.00% during the next five years compared to 16.48% growth over the previous five years of trading.
Novo Nordisk ADR (NYSE: NVO) Trading Performance Indicators
Novo Nordisk ADR (NVO) is currently performing well based on its current performance indicators. A quick ratio of 0.75 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.09. Likewise, its price to free cash flow for the trailing twelve months is 31.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.08, a number that is poised to hit 0.89 in the next quarter and is forecasted to reach 4.11 in one year’s time.
Technical Analysis of Novo Nordisk ADR (NVO)
Novo Nordisk ADR (NYSE: NVO) saw its 5-day average volume 7.14 million, a positive change from its year-to-date volume of 4.45 million. As of the previous 9 days, the stock’s Stochastic %D was 32.26%. Additionally, its Average True Range was 2.64.
During the past 100 days, Novo Nordisk ADR’s (NVO) raw stochastic average was set at 4.71%, which indicates a significant decrease from 19.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 25.54% in the past 14 days, which was lower than the 34.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $120.23, while its 200-day Moving Average is $128.32. Nevertheless, the first resistance level for the watch stands at $107.88 in the near term. At $108.70, the stock is likely to face the second major resistance level. The third major resistance level sits at $109.79. If the price goes on to break the first support level at $105.97, it is likely to go to the next support level at $104.88. The third support level lies at $104.06 if the price breaches the second support level.
Novo Nordisk ADR (NYSE: NVO) Key Stats
Market capitalization of the company is 357.41 billion based on 4,487,532K outstanding shares. Right now, sales total 33,724 M and income totals 12,151 M. The company made 10,511 M in profit during its latest quarter, and 4,024 M in sales during its previous quarter.
